MX2009004718A - Antagonistas de receptor de alk1 y ligando y sus usos. - Google Patents

Antagonistas de receptor de alk1 y ligando y sus usos.

Info

Publication number
MX2009004718A
MX2009004718A MX2009004718A MX2009004718A MX2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A MX 2009004718 A MX2009004718 A MX 2009004718A
Authority
MX
Mexico
Prior art keywords
ligand
alkl
polypeptide
ligand antagonists
ligands
Prior art date
Application number
MX2009004718A
Other languages
English (en)
Inventor
John Knopf
Jasbir Seehra
Asya Grinberg
Ravindra Kumar
Robert Scott Pearsall
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2009004718A publication Critical patent/MX2009004718A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

En ciertos aspectos, la presente invención se refiere al discernimiento de que un polipéptido que comprende una porción de unión de ligando del dominio extracelular de polipéptido de cinasa 1 de tipo activina (ALK1) puede ser utilizado para inhibir angiogénesis in vivo, particularmente en mamíferos que sufren trastornos relacionados con angiogénesis. La descripción también identifica ligandos para ALK1 y demuestra que dichos ligandos tienen actividad pro-angiogénica, y anticuerpos que inhiben la interacción de receptor-ligando.
MX2009004718A 2006-11-02 2007-11-02 Antagonistas de receptor de alk1 y ligando y sus usos. MX2009004718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85659206P 2006-11-02 2006-11-02
PCT/US2007/023217 WO2008057461A2 (en) 2006-11-02 2007-11-02 Alk1 receptor and ligand antagonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2009004718A true MX2009004718A (es) 2009-06-19

Family

ID=39365087

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004718A MX2009004718A (es) 2006-11-02 2007-11-02 Antagonistas de receptor de alk1 y ligando y sus usos.

Country Status (14)

Country Link
US (4) US8455428B2 (es)
EP (2) EP2087001B1 (es)
JP (5) JP2010508816A (es)
KR (3) KR20150008889A (es)
CN (2) CN111518218A (es)
AU (1) AU2007317926A1 (es)
BR (1) BRPI0717964A2 (es)
CA (1) CA2668411C (es)
DK (1) DK2087001T3 (es)
ES (1) ES2612755T3 (es)
IL (2) IL198522A (es)
MX (1) MX2009004718A (es)
RU (2) RU2559532C2 (es)
WO (1) WO2008057461A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8764725B2 (en) 2004-02-09 2014-07-01 Covidien Lp Directional anchoring mechanism, method and applications thereof
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
CN111518218A (zh) 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
ES2554812T3 (es) * 2007-11-09 2015-12-23 Genentech, Inc. Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
CN105963695A (zh) * 2008-05-02 2016-09-28 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
EP2291401A2 (en) * 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
WO2011056494A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
CN108341863A (zh) * 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
KR101421171B1 (ko) * 2011-08-31 2014-07-22 재단법인 제이씨비 공동생물과학연구소 인간 골형성 단백질 수용체 1ａ의 세포외 도메인을 유효성분으로 포함하는 피부 상태 개선용 조성물
MX2014009277A (es) * 2012-02-02 2015-03-03 Acceleron Pharma Inc Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal.
KR102354787B1 (ko) 2013-10-25 2022-01-24 악셀레론 파마 인코포레이티드 섬유화 질환을 치료하기 위한 엔도글린 펩티드
EP3122381A4 (en) * 2014-03-28 2017-11-08 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
MA53883A (fr) 2015-04-06 2021-08-18 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
CN114736307A (zh) * 2015-04-06 2022-07-12 阿塞勒隆制药公司 TGF-β超家族I型和II型受体异多聚体及其用途
BR112017021484A2 (pt) * 2015-06-05 2018-07-03 Novartis Ag anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
US20210403549A1 (en) * 2017-05-17 2021-12-30 Yale University Compounds and compositions that inhibit or prevent lipoprotein entry into the endothelium

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) * 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2104964A1 (en) 1991-02-28 1992-08-29 Ruth Sager Cancer diagnosis and therapy with tumor suppressor genes
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
CA2149441C (en) 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
JP3645258B2 (ja) * 1993-01-12 2005-05-11 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−５
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1997007135A2 (en) 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
EP0938505B1 (en) * 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
US6190660B1 (en) * 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
EP1071765A4 (en) 1998-03-13 2003-01-15 Ludwig Inst Cancer Res ALK-1 REACTS TO TGF-BETA AND CONTINUOUSLY SIGNALS BY SMAD-1 AND SMAD-5
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6413513B1 (en) * 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US20030012792A1 (en) * 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
JP2003509011A (ja) * 1999-06-03 2003-03-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 脈管形成タンパク質およびそれらの使用
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7077836B2 (en) * 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
WO2002011785A2 (en) 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
DE10043481A1 (de) 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
MXPA04003697A (es) 2001-10-31 2005-04-08 Alcon Inc Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
WO2003064628A2 (en) 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
AU2003234734A1 (en) 2002-04-29 2003-11-17 Saint Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
CA2490713A1 (en) 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
AU2003287444A1 (en) 2002-10-31 2004-05-25 The General Hospital Corporation Repairing or replacing tissues or organs
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005044849A2 (en) 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005116850A2 (en) 2004-01-27 2005-12-08 Compugen Ltd. Differential expression of markers in ovarian cancer
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
ES2710048T3 (es) * 2004-07-23 2019-04-22 Acceleron Pharma Inc Anticuerpos antagonistas del receptor ActRII
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
CA2600505C (en) * 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
HUE025608T2 (en) * 2005-09-07 2016-03-29 Amgen Fremont Inc Human monoclonal antibody against activin receptor-like kinase-1 (ALK-1)
US20090170767A1 (en) 2006-05-31 2009-07-02 Beth Israel Deaconess Medical Center Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
CN111518218A (zh) * 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US8642031B2 (en) * 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
ES2554812T3 (es) * 2007-11-09 2015-12-23 Genentech, Inc. Composiciones de antagonistas de quinasa 1 de tipo receptor de activina y métodos de uso
CN105963695A (zh) 2008-05-02 2016-09-28 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof

Also Published As

Publication number Publication date
JP2018127471A (ja) 2018-08-16
CN111518218A (zh) 2020-08-11
WO2008057461A3 (en) 2009-02-26
EP2087001A2 (en) 2009-08-12
JP6348448B2 (ja) 2018-06-27
US20170354731A1 (en) 2017-12-14
JP2010508816A (ja) 2010-03-25
US20080175844A1 (en) 2008-07-24
IL198522A (en) 2017-06-29
CA2668411A1 (en) 2008-05-15
RU2009120695A (ru) 2010-12-10
KR20090085662A (ko) 2009-08-07
US20130344067A1 (en) 2013-12-26
ES2612755T3 (es) 2017-05-18
US20220296708A1 (en) 2022-09-22
CA2668411C (en) 2020-02-25
KR20150008889A (ko) 2015-01-23
JP2020150955A (ja) 2020-09-24
AU2007317926A1 (en) 2008-05-15
RU2013134324A (ru) 2015-01-27
BRPI0717964A2 (pt) 2013-12-17
DK2087001T3 (en) 2017-02-06
US8455428B2 (en) 2013-06-04
JP2015143269A (ja) 2015-08-06
IL198522A0 (en) 2011-08-01
KR101581961B1 (ko) 2016-01-04
KR20170012582A (ko) 2017-02-02
CN101652387A (zh) 2010-02-17
IL253035A0 (en) 2017-08-31
EP3181580A1 (en) 2017-06-21
JP2013199496A (ja) 2013-10-03
RU2559532C2 (ru) 2015-08-10
EP2087001B1 (en) 2016-10-26
WO2008057461A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
MX2009004718A (es) Antagonistas de receptor de alk1 y ligando y sus usos.
WO2009134428A3 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
MX2010005031A (es) Anticuerpos de axl.
WO2009139891A3 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
MA32892B1 (fr) Anticorps anti-cmet
GEP20074252B (en) Antibodies to vla-1
MX2011011825A (es) Anticuerpos humanizados para axl.
WO2009142732A3 (en) Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
GB0724532D0 (en) Trail variants for treating cancer
DE60225673D1 (de) Kappa-opioid-rezeptor-liganden
WO2007024921A3 (en) Combination therapies for inhibiting integrin-extracellular matrix interactions
MX2011013172A (es) Metodos para aumentar adipocitos termogenicos.
EA201000319A1 (ru) Производные азациклилизохинолинона и изоиндолинона в качестве антагонистов гистаминовых рецепторов подтипа 3
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
UA107782C2 (ru) Антагонисты рецепторов fgf-r4
SI2094690T1 (sl) Derivati 2-aza-biciklo(3.1.0)heksana kot antagonisti receptorja za oreksin
MX2009013269A (es) Inhibidores de receptor de cinasas de tirosina y metodos de uso de los mismos.
TW200720467A (en) Atomic layer deposition of ruthenium-containing films using surface-activating agents and selected ruthenium complexes
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
WO2007022273A3 (en) Vegf-activated fas ligands
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
MX2014009277A (es) Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal.
EA201000316A1 (ru) Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
EP1848275A4 (en) LIGANDS OF THE OPIOID RECEPTOR KAPPA

Legal Events

Date Code Title Description
FG Grant or registration